Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis

P. C. De Groen, D. K. McCallum, T. P. Moyer, R. H. Wiesner

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with PBC exhibited variable pharmacokinetic parameters of cyclosporine with two patterns of elimination. The pharmacokientic modeling overestimated the dose needed to achieve the desired trough blood concentrations and was not helpful in establishing daily maintenance doses. These results are similar to conclusions found by others. Frequent and continual monitoring of cyclosporine whole blood trough concentrations is needed to obtain the desired therapeutic trough levels and to avoid toxicity in PBC patients receiving cyclosporine.

Original languageEnglish (US)
Pages (from-to)509-511
Number of pages3
JournalTransplantation Proceedings
Volume20
Issue number2 SUPPL. 2
StatePublished - 1988

Fingerprint

Biliary Liver Cirrhosis
Cyclosporine
Pharmacokinetics
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

De Groen, P. C., McCallum, D. K., Moyer, T. P., & Wiesner, R. H. (1988). Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis. Transplantation Proceedings, 20(2 SUPPL. 2), 509-511.

Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis. / De Groen, P. C.; McCallum, D. K.; Moyer, T. P.; Wiesner, R. H.

In: Transplantation Proceedings, Vol. 20, No. 2 SUPPL. 2, 1988, p. 509-511.

Research output: Contribution to journalArticle

De Groen, PC, McCallum, DK, Moyer, TP & Wiesner, RH 1988, 'Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis', Transplantation Proceedings, vol. 20, no. 2 SUPPL. 2, pp. 509-511.
De Groen PC, McCallum DK, Moyer TP, Wiesner RH. Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis. Transplantation Proceedings. 1988;20(2 SUPPL. 2):509-511.
De Groen, P. C. ; McCallum, D. K. ; Moyer, T. P. ; Wiesner, R. H. / Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis. In: Transplantation Proceedings. 1988 ; Vol. 20, No. 2 SUPPL. 2. pp. 509-511.
@article{76fa2589e6814338911510b65fb9e212,
title = "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis",
abstract = "Patients with PBC exhibited variable pharmacokinetic parameters of cyclosporine with two patterns of elimination. The pharmacokientic modeling overestimated the dose needed to achieve the desired trough blood concentrations and was not helpful in establishing daily maintenance doses. These results are similar to conclusions found by others. Frequent and continual monitoring of cyclosporine whole blood trough concentrations is needed to obtain the desired therapeutic trough levels and to avoid toxicity in PBC patients receiving cyclosporine.",
author = "{De Groen}, {P. C.} and McCallum, {D. K.} and Moyer, {T. P.} and Wiesner, {R. H.}",
year = "1988",
language = "English (US)",
volume = "20",
pages = "509--511",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2 SUPPL. 2",

}

TY - JOUR

T1 - Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis

AU - De Groen, P. C.

AU - McCallum, D. K.

AU - Moyer, T. P.

AU - Wiesner, R. H.

PY - 1988

Y1 - 1988

N2 - Patients with PBC exhibited variable pharmacokinetic parameters of cyclosporine with two patterns of elimination. The pharmacokientic modeling overestimated the dose needed to achieve the desired trough blood concentrations and was not helpful in establishing daily maintenance doses. These results are similar to conclusions found by others. Frequent and continual monitoring of cyclosporine whole blood trough concentrations is needed to obtain the desired therapeutic trough levels and to avoid toxicity in PBC patients receiving cyclosporine.

AB - Patients with PBC exhibited variable pharmacokinetic parameters of cyclosporine with two patterns of elimination. The pharmacokientic modeling overestimated the dose needed to achieve the desired trough blood concentrations and was not helpful in establishing daily maintenance doses. These results are similar to conclusions found by others. Frequent and continual monitoring of cyclosporine whole blood trough concentrations is needed to obtain the desired therapeutic trough levels and to avoid toxicity in PBC patients receiving cyclosporine.

UR - http://www.scopus.com/inward/record.url?scp=0023943473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023943473&partnerID=8YFLogxK

M3 - Article

C2 - 3363652

AN - SCOPUS:0023943473

VL - 20

SP - 509

EP - 511

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2 SUPPL. 2

ER -